| Farhana Jan, MD | |
|
330 Brookline Ave, Boston, MA 02215-5400 | |
| (617) 667-3753 | |
| Not Available |
| Full Name | Farhana Jan |
|---|---|
| Gender | Female |
| Speciality | Dermatology |
| Experience | 21 Years |
| Location | 330 Brookline Ave, Boston, Massachusetts |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1558422584 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | PENDING (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Beth Israel Deaconess Medical Center | Boston, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc | 4486567104 | 1344 |
News Archive
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
eHealth Ontario and Infrastructure Ontario announced today that with the awarding of a contract to CGI Information Systems and Management Consultants Inc., a subsidiary of CGI Group Inc., work can begin on a chronic disease management system (CDMS) that will be used initially as a Diabetes Registry to manage diabetes care.
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
A KAIST team presented a highly customizable neural stimulation method. The research team developed a technology that can print the heat pattern on a micron scale to enable the control of biological activities remotely.
› Verified 1 days ago
| Entity Name | Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043250616 PECOS PAC ID: 4486567104 Enrollment ID: O20040323000519 |
News Archive
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
eHealth Ontario and Infrastructure Ontario announced today that with the awarding of a contract to CGI Information Systems and Management Consultants Inc., a subsidiary of CGI Group Inc., work can begin on a chronic disease management system (CDMS) that will be used initially as a Diabetes Registry to manage diabetes care.
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
A KAIST team presented a highly customizable neural stimulation method. The research team developed a technology that can print the heat pattern on a micron scale to enable the control of biological activities remotely.
› Verified 1 days ago
| Entity Name | Beth Israel Deaconess Medical Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548202641 PECOS PAC ID: 8123936119 Enrollment ID: O20041001000827 |
News Archive
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
eHealth Ontario and Infrastructure Ontario announced today that with the awarding of a contract to CGI Information Systems and Management Consultants Inc., a subsidiary of CGI Group Inc., work can begin on a chronic disease management system (CDMS) that will be used initially as a Diabetes Registry to manage diabetes care.
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
A KAIST team presented a highly customizable neural stimulation method. The research team developed a technology that can print the heat pattern on a micron scale to enable the control of biological activities remotely.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Farhana Jan, MD 550 Tusculum Ave, Cincinnati, OH 45226-1774 Ph: (513) 252-7695 | Farhana Jan, MD 330 Brookline Ave, Boston, MA 02215-5400 Ph: (617) 667-3753 |
News Archive
As previously disclosed, Albany Molecular Research, Inc. ("AMRI" or "the "Company") (NASDAQ: AMRI) received a warning letter, dated August 17, 2010, from the U.S. Food and Drug Administration (FDA) in connection with the FDA's inspection of the Company's pharmaceutical manufacturing facility located in Burlington, Massachusetts.
eHealth Ontario and Infrastructure Ontario announced today that with the awarding of a contract to CGI Information Systems and Management Consultants Inc., a subsidiary of CGI Group Inc., work can begin on a chronic disease management system (CDMS) that will be used initially as a Diabetes Registry to manage diabetes care.
CytoDyn, Inc. has begun full humanization of Cytolin®, the Company's unique immune therapy for treating HIV/AIDS. Although a murine (mouse) version of Cytolin® was used for previous human experience that included some 200 patients successfully treated for up to two years, as well as an encouraging Phase I(b)/II(a) study, the Company believes that a fully-humanized version is necessary for the clinical trial that is expected to follow the current one (described at http://clinicaltrials.gov) for the reasons explained below.
A KAIST team presented a highly customizable neural stimulation method. The research team developed a technology that can print the heat pattern on a micron scale to enable the control of biological activities remotely.
› Verified 1 days ago
Erica Dommasch, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 330 Brookline Ave, Shapiro 2, Boston, MA 02215 Phone: 617-667-3753 | |
Dr. Chantal Louise Cotter, MB BCH BAO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 300 Longwood Ave, Boston, MA 02115 Phone: 617-355-6117 | |
Dr. John J Croke, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany St, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289 | |
Dr. Debjani Sahni, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 725 Albany Street, Shapiro 8, Boston, MA 02118 Phone: 617-638-7420 Fax: 617-638-7289 | |
Dr. Joseph C Kvedar, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 50 Staniford St, Suite 200, Boston, MA 02114 Phone: 617-726-2914 Fax: 617-724-2135 | |
Ryan Char Kelm, Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St # 250, Boston, MA 02114 Phone: 617-724-6960 | |
Dr. David Attar Hashemi, MD, MBA Dermatology Medicare: Medicare Enrolled Practice Location: 50 Staniford St, Boston, MA 02114 Phone: 617-726-2914 |